GRAIL, Inc. GRAL
At closeNov 11, 2026, 4:57 PM EST
After hours · Nov 11, 4:57 PM ET
- YTD
- +46.79%
- 1 year
- +50.67%
- Market cap
- 5.65B
- Revenue (ttm)
- 166.60M
- Profit margin
- -243.80%
- EPS (ttm)
- -9.22
- Shares out
- 44.96M
- Forward P/E
- -15.43
- YTD return
- +46.79%
- 1-year return
- +50.67%
- Volume
- 513.19K
- Avg volume
- 1.04M
- Open
- 130.45
- Previous close
- 124.74
- Day's range
- 124.83 – 133.00
- 52-week range
- 41.50 – 166.48
- Beta
- 2.87
- Analysts
- Buy
- Price target
- 139.44 (+11.0%)
- Earnings date
- Feb 18, 2027
5D -1.93 (-1.51%)
Key statistics
- Enterprise value
- 4.91B
- PEG ratio
- 0.00
- Price / sales
- 33.91
- Price / book
- 2.29
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 3.70%
- Free cash flow
- -112.64M
- Total cash
- 788.68M
- Total debt
- 85.85M
- Return on equity
- -17.31%
- Short % of float
- 18.16%
- 50-day average
- 118.99
- 200-day average
- 78.99
Analyst view
Consensus: buy
- Target (low)
- 100.00
- Target (mean)
- 139.44
- Target (high)
- 175.00
- Strong buy0
- Buy5
- Hold5
- Sell0
- Strong sell0
Next earnings
Feb 18, 2027
Expected Feb 18, 2027. Consensus EPS estimate -1.51.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 18, 2027 | Dec 30, 2026 | -2.38 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | -2.56 | -2.21 | +0.35 | +13.67% |
| Aug 5, 2026 | Jun 30, 2026 | -2.66 | -2.56 | +0.10 | +3.76% |
| May 5, 2026 | Mar 31, 2026 | -2.76 | -2.29 | +0.47 | +17.11% |
| Feb 19, 2026 | Dec 31, 2025 | -3.33 | -2.44 | +0.89 | +26.73% |
| Nov 12, 2025 | Sep 30, 2025 | -3.36 | -2.46 | +0.90 | +26.79% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 10, 2026 | Piper Sandler | main | Neutral | Neutral |
| Nov 5, 2026 | RBC Capital | main | Sector Perform | Sector Perform |
| Oct 13, 2026 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| Oct 13, 2026 | TD Cowen | main | Buy | Buy |
| Oct 2, 2026 | UBS | main | Buy | Buy |
| Oct 1, 2026 | Guggenheim | main | Buy | Buy |
About GRAIL, Inc.
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Sunnyvale, California.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- grail.com
News
Got $10,000? 3 Hot Stocks to Buy That Could Make You a Fortune 
GRAIL, Inc. (GRAL) Presents at 2026 UBS Global Healthcare Conference Transcript 
Grail Exec Says Co. In Conversations With Commercial Payers For Galleri Cancer Test 
Piper Sandler Maintains Neutral on GRAIL, Raises Price Target to $130 
Her Doctor Will Order a $949 Blood Test That Screens for Multiple Cancers. Medicare Will Pay $0 Toward the Test, Leaving Her With the Entire Bill Before Any Coverage Decision in 2029 
RBC Capital Maintains Sector Perform on GRAIL, Raises Price Target to $100 
GRAIL Q3 Earnings Call Ties FDA Review to Pricing and Sales Growth 
Artisan Global Equity Fund Q3 2026 Portfolio Review 
GRAIL, Inc. (GRAL) Q3 2026 Earnings Call Transcript 
What GRAIL (GRAL) Said on Its Q3 Earnings Call
Your note
Sign in to keep a note on GRAL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHASE WILLIAM J | Director | Stock Award(Grant) | Oct 14, 2026 | 43,131 |
| DING CHUN R | Beneficial Owner of more than 10% of a Class of Security | Sale | Jun 30, 2025 | 0 |
| FREIDIN AARON | Chief Financial Officer | Sale | Oct 4, 2026 | 225,364 |
| ILLUMINA INC | Beneficial Owner of more than 10% of a Class of Security | Sale | Nov 16, 2025 | 3,502,130 |
| KREVANS SARAH | Director | Stock Award(Grant) | Jun 21, 2026 | 42,628 |
| MIZELL STEVEN | Director | Stock Award(Grant) | Oct 14, 2026 | 42,978 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Farallon Capital Management LLC | 9.26% | 4,161,584 | 522.86M | Jun 29, 2026 |
| Baker Bros. Advisors, LP | 8.96% | 4,028,614 | 506.16M | Jun 29, 2026 |
| Blackrock Inc. | 7.96% | 3,577,075 | 449.42M | Jun 29, 2026 |
| State Street Corporation | 5.31% | 2,385,514 | 299.72M | Jun 29, 2026 |
| Primecap Management Company | 4.85% | 2,180,106 | 273.91M | Jun 29, 2026 |
| Sessa Capital IM, L.P. | 4.53% | 2,037,518 | 255.99M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund | 3.51% | 1,579,791 | 198.48M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.73% | 1,228,548 | 154.35M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.38% | 1,068,030 | 134.19M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.18% | 979,351 | 123.05M | Sep 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.01% | 452,483 | 56.85M | Aug 30, 2026 |
| iShares Trust-iShares Russell 2000 Value ETF | 0.86% | 387,264 | 48.66M | Sep 29, 2026 |